Pharvaris Presents Data Supporting Combined Use of Deucrictibant IR/XR for Angioedema
Event summary
- Pharvaris presented data at CIIC Spring 2026 Conference supporting combined use of deucrictibant IR (20 mg) and XR (40 mg) for hereditary angioedema (HAE).
- Analysis demonstrated adequate safety margins for combined administration of deucrictibant XR for prophylaxis and IR for breakthrough attacks.
- Post-hoc analysis of CHAPTER-1 study showed comparable efficacy of icatibant-treated attacks in placebo and deucrictibant arms.
- Pharvaris aims to submit NDA for deucrictibant IR in H1 2026 and expects CHAPTER-3 topline data in Q3 2026.
The big picture
Pharvaris' data presentation marks a strategic pivot toward combination therapy for bradykinin-mediated angioedema, potentially expanding its market reach. The approach aligns with industry trends toward oral alternatives to injectables, though success hinges on regulatory approval and clinical validation. The company's pipeline includes both prophylactic and on-demand formulations, targeting a $2B+ global HAE market.
What we're watching
- Regulatory Pathway
- Whether Pharvaris can secure approval for deucrictibant IR as an on-demand treatment by H1 2026.
- Clinical Validation
- The pace at which CHAPTER-3 data will confirm deucrictibant XR's prophylactic efficacy.
- Commercial Strategy
- How Pharvaris positions the combination therapy against existing injectable treatments.